1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics, February 2016 (p6)

Healthcare Analysis & Statistics, February 2016 (p6)

151-180 of about 200 reports

Hepatitis C: Update Bulletin [February 2016]

Hepatitis C: Update Bulletin [February 2016]

  • $ 1077
  • Industry report
  • February 2016

Gain new KOL insights on the latest events that have the potential to shape the hepatitis C virus (HCV) treatment landscape. Topics covered include KOL insights on how Merck & Co.’s Zepatier (elbasvi ...

  • Industries : Therapy
  • Countries : United States
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • Industry report
  • January 2016

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : European Union, United States
Biosimilars in Oncology: KOL Insight

Biosimilars in Oncology: KOL Insight

  • $ 8379
  • Industry report
  • January 2016

IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologists that make treatment decisions in life or death situations aren't yet ready to accept biosimilars ...

  • Industries : Medical Biotechnology, Therapy, Health Services, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States
Medical Affairs Reputations (US): Rheumatoid Arthritis

Medical Affairs Reputations (US): Rheumatoid Arthritis

  • $ 7638
  • Industry report
  • November 2015

Is your rheumatoid arthritis Medical Affairs team leading the pack or following on behind?How are Medical Affairs teams from challenger brands shaping up when compared with those from well-established ...

  • Industries : Therapy, Medical Biotechnology, Health Services
  • Countries : United States
Medical Affairs Reputations (EU5): Rheumatoid Arthritis

Medical Affairs Reputations (EU5): Rheumatoid Arthritis

  • $ 7638
  • Industry report
  • November 2015

Is your rheumatoid arthritis Medical Affairs team leading the pack or following behind? How well are the Medical Affairs teams from biosimilar manufacturers performing when compared with those from w ...

  • Industries : Health Services, Medical Biotechnology
  • Countries : United States
Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7974
  • Industry report
  • July 2015

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting KRAS-mutation ...

  • Industries : Therapy, Cancer, General Medicine and Specialty Medicine
  • Countries : United States
Physician Views: Assessing the outlook for Novartis' Entresto

Physician Views: Assessing the outlook for Novartis' Entresto

  • $ 781
  • Industry report
  • July 2015

Novartis has gained earlier than expected US approval for its new heart failure treatment Entresto, which is forecast to be the biggest new drug approval of 2015.Much initial focus is on the pricing of ...

  • Industries : Therapy, Health Services, Pharmaceutical
  • Countries : United States
Physician Views: Can Lundbeck and Otsuka's newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?

Physician Views: Can Lundbeck and Otsuka's newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?

  • $ 781
  • Industry report
  • July 2015

FDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – delivers a third atypical antipsychotic to the US market for the treatment of both schizophrenia and majo ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States
Physician Views: Gauging doctors’ enthusiasm for newest wave of Alzheimer’s candidates

Physician Views: Gauging doctors’ enthusiasm for newest wave of Alzheimer’s candidates

  • $ 781
  • Industry report
  • July 2015

There are an estimated 5.3 million Americans with Alzheimer’s disease (AD), a number that is expected to grow as the Baby Boomers continue to age, which explains why drugmakers have not shied away from ...

  • Industries : Therapy, Mental Health, Pathology
  • Countries : United States
Medical Affairs Reputations (US): Multiple Sclerosis

Medical Affairs Reputations (US): Multiple Sclerosis

  • $ 7638
  • Industry report
  • July 2015

Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition ...

  • Industries : Health Services
  • Countries : Europe
Medical Affairs Reputations (EU5): Multiple Sclerosis

Medical Affairs Reputations (EU5): Multiple Sclerosis

  • $ 7638
  • Industry report
  • July 2015

Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition ...

  • Industries : Health Services
  • Countries : Europe
Physician Views: How have recent data, study design events shaped doctors’ thinking on lead NASH agents

Physician Views: How have recent data, study design events shaped doctors’ thinking on lead NASH agents

  • $ 781
  • Industry report
  • June 2015

Biotech is a notoriously volatile sector, and pure-play nonalcoholic steatohepatitis (NASH) drug developers have for the past couple years occupied one of the more volatile neighbourhoods within it thanks ...

  • Industries : Pathology
  • Countries : United States
Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer

Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer

  • $ 781
  • Industry report
  • June 2015

The data presented at this year's ASCO annual meeting, which has subsequently fuelled the most debate, is likely that from Bristol-Myers Squibb's Checkmate-057 study, assessing its PD-1 inhibitor Opdivo ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States
Physician Views: Assessing new competitive trends in the oral anticoagulant market

Physician Views: Assessing new competitive trends in the oral anticoagulant market

  • $ 781
  • Industry report
  • June 2015

The new class of oral anticoagulants – comprising the Factor Xa inhibitors Xarelto (Bayer/Johnson & Johnson), Eliquis (Bristol-Myers Squibb) and Savaysa (Daiichi Sankyo) and the thrombin inhibitor Pradaxa ...

  • Industries : Health Services
  • Countries : United States
Physician Views: Gauging oncologists’ reaction to ASCO’s new tool for rating cancer drugs

Physician Views: Gauging oncologists’ reaction to ASCO’s new tool for rating cancer drugs

  • $ 781
  • Industry report
  • June 2015

The rising price of cancer drugs in the US has drawn plenty of criticism, and can be particularly frustrating for physicians and patients given the lack of transparency about how much bang they are getting ...

  • Industries : Therapy, Health Services, Oncology
  • Countries : United States
Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

  • $ 781
  • Industry report
  • June 2015

Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, European Union
Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

  • $ 634
  • Industry report
  • June 2015

The question of whether to approve Regeneron and Sanofi’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) never really seemed to be in doubt at FDA’s Endocrinologic and Metabolic Drugs Advisory ...

  • Industries : Therapy
  • Countries : United States, European Union
Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer

Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer

  • $ 781
  • Industry report
  • June 2015

Much of the debate around cancer immunotherapy at the recent ASCO annual meeting focused on the commercial positioning of a new class of product – the PD-1/PD-L1 inhibitors – in second-line, non-small-cell ...

  • Industries : Therapy
  • Countries : United States
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (US)

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (US)

  • $ 7638
  • Industry report
  • May 2015

Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists. Personalised Medicines ...

  • Industries : Health Services
  • Countries : United States
Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?

Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?

  • $ 781
  • Industry report
  • May 2015

Drugmakers may finally have cracked the code to developing safe and effective inhibitors of the calcitonin gene-related peptide (CGRP), a neuropeptide long believed to be associated with migraine headaches ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, OTC, Health Services
  • Countries : United States
Physician Views: Do doctors share industry’s desire for the FDA to relax its policies on off-label promotion of drugs?

Physician Views: Do doctors share industry’s desire for the FDA to relax its policies on off-label promotion of drugs?

  • $ 781
  • Industry report
  • May 2015

Industry appears to be making a concerted push to pressure the FDA to relax what they believe to be overly restrictive policies concerning the off-label promotion of drugs, an effort that began picking ...

  • Industries : Health Services
  • Countries : United States
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

  • $ 7638
  • Industry report
  • May 2015

Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists. Personalised Medicines ...

  • Industries : Health Services
  • Countries : France, Germany, Spain, Italy
Physician Views: Which companies excel in diabetes drug marketing and why?

Physician Views: Which companies excel in diabetes drug marketing and why?

  • $ 781
  • Industry report
  • May 2015

With both the insulin and non-insulin segments of the diabetes market expected to become more competitive through to the end of this decade (see FirstWord Lists: Blockbuster diabetes drugs 2014 and 2020), ...

  • Industries : Chronic Disease, Therapy, Pharmaceutical, Prescription Drug, Pathology
  • Countries : United States
Physician Views: Have expectations been reset for Puma Biotechnology's neratinib in HER2+ breast cancer?

Physician Views: Have expectations been reset for Puma Biotechnology's neratinib in HER2+ breast cancer?

  • $ 781
  • Industry report
  • May 2015

Investors appear to be resetting their expectations for Puma Biotechnology's experimental HER2-positive breast cancer treatment neratinib. An abstract released last week – ahead of this year's ASCO ...

  • Industries : Cancer
Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

  • $ 781
  • Industry report
  • April 2015

Lingering concerns have been hanging over AstraZeneca’s Onglyza and Takeda’s Nesina since 2013 when detailed analyses from respective cardiovascular (CV) outcomes studies suggested the DPP-IV inhibitors ...

  • Industries : Chronic Disease
  • Countries : United States
Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?

Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?

  • $ 781
  • Industry report
  • April 2015

New data presented at the annual meeting of the American Association for Cancer Research (AACR) this past week has further emphasised the paradigm shift in cancer therapy that PD-1 inhibitors offer.Focusing ...

  • Industries : Therapy
  • Countries : United States
Physician Views: Can Intarcia's implantable GLP-1 treatment revolutionise the diabetes market?

Physician Views: Can Intarcia's implantable GLP-1 treatment revolutionise the diabetes market?

  • $ 781
  • Industry report
  • April 2015

Intarcia has previously suggested that it is the highest-valued privately owned biotech company in history. This claim is heavily built around the potential success of ITCA 650; a matchstick-sized, subcutaneous ...

  • Industries : Chronic Disease, Therapy, Pathology
  • Countries : United States, World
Physician Views: The hepatitis C pricing war - what impact on prescribers?

Physician Views: The hepatitis C pricing war - what impact on prescribers?

  • $ 781
  • Industry report
  • January 2015

In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Viekira Pak to Express Scripts at an undisclosed discount in exchange for exclusive access to the pharmacy benefit ...

  • Industries : Pathology
  • Countries : United States
Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

  • $ 781
  • Industry report
  • January 2015

Novartis has become the first player to bring to market an interleukin-17A inhibitor, most recently announcing on Monday that the European Commission approved Cosentyx for the treatment of moderate-to-severe ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Europe, European Union
Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies

Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies

  • $ 3534
  • Industry report
  • December 2014

As the cancer drug market continues to face significant challenges in an environment of rising R&D costs, value-based pricing, demands for real world evidence and tougher regulation, the role of Medical ...

  • Industries : Cancer, Health Services

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on